We are actively seeking commercial partners who share our dedication to bringing relief to patients with chronic cough.

Haduvio Overview:

• 24 issued US and foreign patents with key patents expiring in the US in 2039 and additional patent applications with terms, if issued, expiring between 2032 and 2045.
• Only oral dual acting MOA in clinical development that works both centrally and peripherally along the complete cough pathway to control cough.